Seeking Alpha
11 Jun 2026, 18:42 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Enliven Therapeutics reported updated Phase 1 ENABLE trial data for ELVN-001 in patients with previously treated Chronic Myeloid Leukemia (CML). — Positive clinical data updates for a lead candidate typically drive significant valuation changes for small-cap biotech firms.
+0.60Which stocks this story touches
The company is presenting updated clinical trial data for its lead candidate, which is typically a positive catalyst for biotech sentiment.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
12h ago
